Alexion Pharmaceuticals
E505487
Alexion Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for rare and severe diseases, particularly in the field of complement biology.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Alexion Pharmaceuticals canonical | 7 |
How this entity was disambiguated
This entity first appeared as the object of triple T5248776 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Alexion Pharmaceuticals Context triple: [AstraZeneca, hasSubsidiary, Alexion Pharmaceuticals]
-
A.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
B.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
C.
Genmab
Genmab is a Danish biotechnology company specializing in the development of antibody-based cancer therapies.
-
D.
Ariad Pharmaceuticals
Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
-
E.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Alexion Pharmaceuticals Target entity description: Alexion Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for rare and severe diseases, particularly in the field of complement biology.
-
A.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
B.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
C.
Genmab
Genmab is a Danish biotechnology company specializing in the development of antibody-based cancer therapies.
-
D.
Ariad Pharmaceuticals
Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
-
E.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
public company ⓘ |
| acquiredBy | AstraZeneca ⓘ |
| acquisitionAnnouncedOn | 2020-12-12 ⓘ |
| acquisitionCompletedOn | 2021-07-21 ⓘ |
| country |
United States
ⓘ
linked to:
United States of America
|
| developsTreatmentFor |
atypical hemolytic uremic syndrome
ⓘ
generalized myasthenia gravis ⓘ hypophosphatasia ⓘ lysosomal acid lipase deficiency ⓘ neuromyelitis optica spectrum disorder ⓘ paroxysmal nocturnal hemoglobinuria ⓘ |
| divisionOf |
AstraZeneca Rare Disease
ⓘ
linked to:
AstraZeneca
|
| focusesOn | complement-mediated disorders ⓘ |
| formerHeadquartersLocation |
New Haven, Connecticut, United States
ⓘ
linked to:
New Haven, Connecticut
|
| foundedBy |
Leonard Bell
ⓘ
Stephen Squinto ⓘ |
| foundedIn | 1992 ⓘ |
| hasEmployeeCountRange | >= 3000 employees (approximate) ⓘ |
| headquartersLocation |
Boston, Massachusetts, United States
ⓘ
linked to:
Boston, Massachusetts
|
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| keyDrug |
eculizumab
ⓘ
ravulizumab ⓘ |
| listedOn | NASDAQ ⓘ |
| notableProduct |
Andexxa
ⓘ
Kanuma ⓘ Soliris ⓘ Strensiq ⓘ Ultomiris ⓘ |
| parentCompany | AstraZeneca ⓘ |
| regulatoryApproval |
FDA approval for Kanuma in LAL-D
ⓘ
FDA approval for Soliris in NMOSD ⓘ FDA approval for Soliris in PNH ⓘ FDA approval for Soliris in aHUS ⓘ FDA approval for Soliris in gMG ⓘ FDA approval for Strensiq in hypophosphatasia ⓘ FDA approval for Ultomiris in PNH ⓘ FDA approval for Ultomiris in aHUS ⓘ |
| researchFocus |
complement inhibition
ⓘ
rare hematologic diseases ⓘ rare metabolic diseases ⓘ rare neurologic diseases ⓘ rare renal diseases ⓘ |
| specializesIn |
complement biology
ⓘ
therapies for rare diseases ⓘ therapies for severe diseases ⓘ |
| tickerSymbol | ALXN ⓘ |
| website | https://alexion.com ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Alexion Pharmaceuticals Description of subject: Alexion Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for rare and severe diseases, particularly in the field of complement biology.
Referenced by (7)
Full triples — surface form annotated when it differs from this entity's canonical label.